The folder is still growing
October–November 2026 clinical research and safety notices
What does “approved” actually cover?
His first assignment was blood sugar. Now the folder needs an index. Subject One offers to label everything “approved.” Doctide hands him a finer pen. “For whom? For what? Which product?” He starts again, more carefully.
What changes here
Approval belongs to defined products, uses and populations. It does not make every possible use established or remove the safety warnings. [1]
Read the study details & dates
A pediatric diabetes expansion
Current Mounjaro labeling includes type 2 diabetes in patients aged 10 years and older. That does not automatically extend Zepbound’s separate indications to children. [1]
A cardiovascular indication
Mounjaro gained a cardiovascular-risk indication for adults with type 2 diabetes at high cardiovascular risk. SURPASS-CVOT established noninferiority to dulaglutide, not superiority; the reported hazard ratio was 0.92 with a confidence interval crossing 1. [2] [1]
Counterfeit pens: a separate product-quality warning
MHRA reported a Birmingham seizure of over 12,000 counterfeit retatrutide and tirzepatide pens. Their contents and quality were uncertain. This enforcement notice is not a clinical trial, a new approval, or evidence about authentic trial supplies or licensed products; it reports no patient outcomes. [3]
Women in digital care: useful evidence, without a comparison group
A UK self-pay digital-care cohort enrolled 8,127 adult women; 99.8% initiated tirzepatide. Among 7,297 with six-month weights, mean loss was 16.1 kg (95% CI 15.9–16.2), or 15.5% of baseline weight. This complete-case, uncontrolled observation cannot separate medication effects from structured support or selection and missing-data effects. It is not a randomized comparison or a new approved indication. The abstract reports no serious treatment-related adverse events, which does not mean no side effects or establish long-term safety. Program operators employed two authors; consulting relationships were also disclosed. [4] [5]
Hormone therapy: no sustained statistically significant difference
The same retrospective study separately matched 1,476 midlife women using tirzepatide: 492 with hormone therapy and 984 without. Mean weight loss was 6.6% versus 5.9% at three months (p=0.031); later weight-change differences were not statistically significant. These findings cannot establish equivalence, causation or comparative effectiveness against semaglutide. The abstract supplies no new adverse-event analysis, and does not specify tirzepatide formulation. This is an observational conference report, not a new indication. [6]
Compounded vials recalled over sterility assurance
FDA enforcement data records a voluntary Class II recall by Apothecary Pharma LLC of specified lots of compounded tirzepatide injection, distributed nationwide in the United States, because sterility could not be assured. The record identifies sterile multidose vials, NDC 85091-001-18, and lists the affected lots. This concerns that compounded preparation, not a recall of Mounjaro or Zepbound and not a finding about clinical-trial supplies. The accessible record gives no patient injury or death counts and no patient-level causality assessment; absence of those fields cannot be read as absence of harm. These September–October events were newly added to this journey on October 23, not newly initiated today. [7]
Kidney response: an exploratory SURPASS-4 subgroup
An analysis of 220 participants with type 2 diabetes and stage 3 chronic kidney disease from the completed phase 3 SURPASS-4 trial (NCT03730662) compared tirzepatide (107) with insulin glargine (113), with mean follow-up of 24 months. Rapid kidney-function decline, defined by an eGFR slope of at most −5 mL/min/year, occurred in 5% versus 13%. Investigators examined treatment effects across baseline protein-concentration thirds; benefits appeared concentrated in the highest groups, with little or none in lower groups. This exploratory subgroup finding does not validate a clinical selection test. Confidence intervals, multiplicity handling and new adverse-event results were absent. The abstract lists NIDDK, Lilly and Renalytix support; a full report and independent validation are needed. [8] [9]
A serious kidney case: suspected association, not proven causation
A case report describes a 47-year-old woman with edema, proteinuria and biopsy-confirmed membranous nephropathy after prolonged compounded-tirzepatide exposure. Kidney filtration was preserved. Proteinuria worsened during follow-up, then improved after lisinopril initiation and resumption of an FDA-approved tirzepatide product; planned immunosuppression was deferred. Investigators suspected a drug-related process but explicitly could not establish causality. Spontaneous remission and other treatment effects remain possible. One uncontrolled case cannot show that compounded tirzepatide caused the illness, that licensed tirzepatide cured it, or how often it occurs. The report does not identify a compounded-product lot or connect this case to the separate FDA recall. [10]
Carolina Infusion compounded syringes: separate sterility-assurance recall
FDA enforcement event 99867 records a voluntary Class II recall by Carolina Infusion, LLC, Ridgeland, South Carolina, distributed nationwide within the United States. The affected records (D-0017-2027 and D-0027-2027 through D-0030-2027) cover specified lots of compounded injectable tirzepatide alone and tirzepatide/cyanocobalamin (vitamin B12), supplied in patient-specific syringes. FDA lists lack of sterility assurance related to formulation water and processing equipment. The linked records identify the precise formulations, concentrations, lots and beyond-use dates; these identifiers are not administration instructions. This is a product-quality enforcement action, not a clinical trial or a recall of Mounjaro or Zepbound. The October 14 dataset lists the recall as ongoing; that historical status does not independently establish its status today. The records contain no patient injury or death counts or patient-level causality assessments, so no absence of harm can be inferred. These are earlier events newly documented in this journey, not a recall initiated today. [11]
Reporting signals cannot rank clinical safety
A retrospective FAERS analysis (January 2022–June 2026) compared semaglutide-only and tirzepatide-only reports using reporting odds ratios, adjusted regression and false-discovery-rate correction. Semaglutide reports more often involved gastric-emptying impairment, obstruction/ileus, kidney injury, pancreatitis, vomiting and optic ischaemic neuropathy; alopecia reporting favored the opposite direction. Adjusted hospitalization and death reporting odds were higher with semaglutide. These are reporting patterns, not incidence, comparative clinical risk or established causality. The abstract does not resolve formulation-specific risks. Only the publisher abstract was reviewed; full tables were inaccessible. [12] [13]
Severe low sodium: a possible association in one patient
An uncontrolled case cannot establish causation or frequency. A woman with type 2 diabetes and severe obesity, taking insulin and long-term torsemide, developed reduced appetite, weakness and drowsiness 10 days after tirzepatide administration. Sodium was 104 mmol/L, with findings compatible with inappropriate antidiuretic hormone secretion. Urinary sodium remained elevated after diuretic withdrawal. Sodium and symptoms improved with treatment. The author describes a potential association; concurrent medication and reduced intake complicate attribution. Brand, formulation and age are not specified in the accessible abstract. This is a serious human safety report, not a new regulator decision or a demonstrated risk for every tirzepatide product. [14]
TOGETHER-PsA: combination treatment at 52 weeks
The phase 3b TOGETHER-PsA trial (NCT06588296) was randomized but open-label: ixekizumab plus tirzepatide (138 adults) versus ixekizumab alone (133). Participants had active psoriatic arthritis and obesity, or BMI >27 to <30 with a weight-related comorbidity. At 52 weeks, ACR50 responses were 43.7% versus 15.7%; difference 28.0 percentage points (95% CI 17.1–38.9). Prespecified week-52 analyses used logistic regression or linear models, without multiplicity control; p-values were nominal. Only 71.6% completed study treatment. Authors described adverse events as consistent with established profiles and adverse-event discontinuations as comparable, but supplied no numerical serious-event/death counts or causality assessments in the retrieved text. Tables were not reviewed; this is not evidence of no harm. Authors include Lilly employees. This conference abstract concerns combination therapy, not tirzepatide alone or a new approved indication; the 52-week findings are separate from the earlier 36-week primary endpoint. [15]
FDA requires a warning about potentially permanent vision loss
FDA requires a NAION warning for marketed GLP-1 medicines, explicitly including Mounjaro and Zepbound. NAION is a rare optic-nerve condition that can cause permanent vision loss. FDA concludes there is a potential increased risk, not proven causation in every reported case. Its pooled analysis of 126 randomized trials found 6.4 versus 3.8 probable events per 100,000 person-years with GLP-1 medicines versus placebo or other glucose-lowering medicines. These are class-level rates, not estimates specific to this medicine or formulation. In a separate Sentinel cohort of adults with type 2 diabetes, risk was higher versus DPP-4 inhibitors but not statistically significantly higher versus SGLT-2 inhibitors. This records the required labeling change; it does not confirm every individual label has already been revised. FDA advises prompt medical contact for sudden painless vision loss or other visual changes. [16]
Resistance exercise reduced—but did not prevent—lean-tissue loss
T-REx randomized 120 middle-aged or older adults with overweight/obesity (men and postmenopausal women) to injectable tirzepatide with supervised resistance exercise or usual activity for 40 weeks. There was no drug-free comparator. Lean soft tissue fell by 3.57 versus 4.67 kg, respectively; it is not synonymous with skeletal muscle. Strength improved with exercise but declined without it. Weight and fat reductions were similar. Age/sex-adjusted mixed models used the authors’ intention-to-treat population (at least one intervention exposure), assuming missing-at-random data; co-primary outcomes used Bonferroni correction. This single-center study does not establish long-term effects or generalize to other medicines. Gastrointestinal symptoms were common. Six serious adverse events were assessed as unrelated to the assigned interventions. Two participants withdrew after breast-cancer diagnoses; these remain serious diagnoses, not temporary illness. [17]
What this does not establish
Keep Mounjaro’s diabetes/CV uses separate from Zepbound’s weight-management/OSA uses. Approved indications are not interchangeable with every promising trial endpoint.
Original sources
- Current Mounjaro prescribing information, revised August 2026
- Lilly cardiovascular approval announcement (sponsor, August 2026)
- MHRA counterfeit-pen enforcement notice, October 15, 2026 (UK regulator)
- Deanfield et al., Nature Medicine, October 16, 2026: observational digital-care cohort (accessible article sections)
- PubMed: study abstract and competing-interest disclosure, PMID 42888249
- Castaneda et al., The Menopause Society 2026, abstract S-1, page 1 (retrospective conference study)
- FDA enforcement record D-0036-2027, event 99952; report October 14, 2026; retrieved October 23
- Satake et al., ASN Kidney Week 2026, FR-OR037 (primary conference abstract; industry-supported)
- ClinicalTrials.gov NCT03730662: SURPASS-4 phase 3 registry; accessed October 24, 2026
- Agrawal et al., ASN Kidney Week 2026, FR-PO0736 (primary case-report abstract)
- FDA enforcement event 99867, records D-0017-2027 and D-0027-2027 through D-0030-2027; report October 14, 2026; retrieved October 26 (dataset last updated October 14)
- Arslan, Endocrine: publisher abstract, DOI 10.1007/s12020-026-04840-z (issue date displayed December 1, 2026)
- NCBI MedGen bibliography: online publication October 29, 2026; PMID 42955519
- Prasad, Indian Journal of Pharmacology, DOI 10.4103/ijp.ijp_205_26: indexed PubMed abstract, PMID 42969999
- Merola et al., ACR Convergence 2026 abstract 2942 (conference abstract; Lilly authors)
- FDA Drug Safety Communication, November 9, 2026: required NAION safety labeling changes
- Green et al., Nature Medicine, November 9, 2026: T-REx randomized trial
Historical sources reviewed October 11, 2026. The October 15 MHRA notice was reviewed October 16; this targeted addition does not imply a fresh review of every earlier trial. October 20: checked the October 16 digital-care study’s accessible abstract, cohort/results sections and PubMed competing-interest disclosure. Full methods and supplementary safety tables could not be retrieved; this is a limited-source update, not a full-paper review. October 23: targeted review of the newly linked primary conference abstract(s) and FDA enforcement API record (dataset last updated October 14). Earlier source-review dates and fictional scenes remain unchanged. October 24: targeted review of the October 23 ASN abstracts added below; these are preliminary conference reports, not full-paper reviews. Historical review dates and fictional scenes are unchanged. October 26: targeted review of FDA enforcement event 99867 and the relevant individual product records; dataset dated October 14. Earlier trial sources and fictional scenes were not re-reviewed. November 2: targeted review of the publisher-hosted FAERS abstract and NCBI bibliographic date. The publisher displays a later issue date. Full-text methods and tables were not accessible; earlier sources and fictional scenes were not re-reviewed. November 4: targeted review of the indexed PubMed abstract and bibliographic record for PMID 42969999, retrieved through search. Direct article-page and full-text retrieval failed; this is an abstract-only update. The November issue date, November 2 article date and November 4 editorial addition are distinct. Earlier sources and fictional scenes were not re-reviewed. November 7: targeted review of the indexed primary ACR abstract text. Direct page retrieval returned an access error; linked figures and safety tables were not available for review. Review date is distinct from the future scheduled presentation. Earlier sources and fictional scenes were not re-reviewed. November 10: reviewed the November 9 FDA safety communication, including its product table, pooled randomized evidence and comparator-dependent Sentinel findings. This targeted review does not redate earlier sources or confirm implementation in every product label. November 11: targeted review of the T-REx primary paper’s methods, results and safety narrative. Detailed adverse-event tables were not separately retrievable. Earlier evidence and fiction were not re-reviewed.
Journal update record
2026-10-11 · Published the documented development journey in six chapters, separating fictional scenes from laboratory, animal and human evidence.
2026-10-16 · Added the October 15 UK counterfeit-pen warning, separately from clinical evidence and licensed-product safety. No fictional scene or historical review date changed.
2026-10-20 · Added the October 16 women’s digital-care cohort, separating observational findings from approval and keeping missing-data, short-follow-up and author-conflict limitations visible. Review was limited to accessible article sections and the indexed abstract/disclosures.
2026-10-23 · Added the menopause cohort’s nonsustained association and the FDA-recorded compounded-vial recall, preserving the original recall dates and distinguishing licensed products.
2026-10-24 · Added exploratory SURPASS-4 kidney findings and a serious kidney case report, keeping compounded and licensed products distinct and the authors’ uncertain causality assessment visible.
2026-10-26 · Added the FDA-recorded Carolina Infusion compounded-syringe recall, preserving September 10 initiation, October 8 classification and October 14 reporting dates. Distinguished specific formulations and lots from licensed products; patient outcomes are not reported in these records. Historical chapters and fiction are unchanged.
2026-11-02 · Added the previously pending October 29 FAERS paper after verifying its publisher abstract. Preserved the distinction between reporting signals and clinical risk, explicit serious outcomes, publication dates and limited review scope. Fiction and historical review dates are unchanged.
2026-11-04 · Added a new severe low-sodium case report, preserving concurrent medicines, uncertain causality and abstract-only review limits. Historical chapters and fiction are unchanged.
2026-11-07 · Added the 52-week combination-treatment congress abstract, preserving open-label design, nominal analyses and limited numerical safety reporting. The scheduled presentation has not yet occurred; no new indication is inferred.
2026-11-10 · Added FDA’s November 9 NAION warning requirement, preserving possible permanent harm, qualified causality and class-level versus product-specific evidence. Fiction and historical chapters are unchanged.
2026-11-11 · Added the November 9 T-REx paper, including lean-tissue loss, comparator limitations and serious-event reporting. Historical chapters and fiction are unchanged.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story